The Histopathological Study and Expression of Immunohistochemical Markers in Central Nervous System Tumours – an institutional study.

Dr.Neelu Vashist; Dr.Nilima Soni; Dr.S.N.Gautam; Dr.R.K.Singh

Volume : IX, Issue : X, October - 2019

The Histopathological Study and Expression of Immunohistochemical Markers in Central Nervous System Tumours – an institutional study.

Dr. Neelu Vashist, Dr. Nilima Soni, Dr. S. N. Gautam, Dr. R. K. Singh

Abstract :

Introduction: Central Nervous System Tumours are not frequent tumours but still the primary CNS tumours continue to be among the top ten causes of cancer related deaths in the world .The GMC ,Kota being the biggest draining hospital in the Kota region, with a well known neurodisorder service, but lacking an accurate data on the CNS tumour epidemiology ,mandates the need for this study. Aim: To provide the spectrum of CNS tumours in the Institute with respect to age , sex & clinical presentation and utility of IHC. Material and Methods:Material comprised of all the CNS tumours.The 3 year study comprising a total of 200 specimens formed the basis of this study. The histological and the Immunohistochemistry findings were correlated. Results: Primary CNS tumours accounted for the majority of the CNS tumours comprising 96.5% of the cases, rest 3.5% being metastatic Glial tumours comprised the largest category.Among the glial tumours,astrocytomas were the commonest ( 31.5% of all CNS tumours), of which 36.5% were GBM, followed by meningiomas ( 18.5%), peripheral nerve sheath tumours, ependymal tumours, emyonal tumours, craniopharyngiomas, Mixed tumours, gliosarcomas, choroid plexus tumours, Oligodendroglioma and hemangioblastomas.Metastatic tumours, that constituted 3.5% of all the CNS tumours were most common in the sixth and seventh decades of life. Immunohistochemistry played an instrumental role in the diagnosis and evaluation of certain lesions. Conclusion: This study has highlighted the relative frequency of different intracranial space occupying lesions in the region.